Trending Topic

A dynamic close-up visualization of red blood cells and glucose molecules inside a human artery
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Jennifer N Clements, Kennedy Howard, Emory Moss

Approximately 20–34% of hospitalized patients have a diagnosis of diabetes, while many others experience stress hyperglycaemia, both increasing the occurrence of dysglycaemia in the hospital.1 Hyperglycaemia is associated with increased infection rates and higher mortality rates. Conversely, hypoglycaemia can lead to adverse neurological outcomes, prolonged hospital stays, as well as increased mortality.1 In spite of current guidelines […]

Diana Isaacs, ADCES 2022: Diabetes technology update and impact on time in range

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 1st 2022

It’s an exciting time in diabetes with several technologies available on the horizon. Advances in technology offer new choices for insulin pumps, connected “smart” pens, continuous glucose monitors (CGM) and automated insulin delivery systems. In this touchENDOCRINOLOGY interview, Dr Diana Isaacs (Endocrine Clinical Pharmacy Specialist, Cleveland Clinic, Cleveland, OH, USA) discusses these technologies and explores how they have shown dramatic effects on glycaemic management and time in range.

The abstract entitled: ‘Diabetes Technology Update and Impact on Time in Range‘ was presented at the Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, 12-15 Aug, 2022.

Questions:

  1. Why is time in range so important in diabetes management? (0:15)
  2. Could you give us a brief overview of the latest advances in insulin pumps, connected “smart” pens, continuous glucose monitors and automated insulin delivery systems? (1:18)
  3. What clinical evidence supports the use of these new technologies? (4:44)
  4. How can we optimise the use of these technologies to maximise the impact on timein range? (5:43)

Disclosures: Diana Isaacs is a consultant for Eli Lilly, and Sanofi; and is a speaker’s bureau participant for Dexcom, Abbott, Bayer, Insulet, Medtronic, Cequr, and Novo Nordisk.

Support: Interview supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Recorded as a highlight of ADCES 2022

Click here for more related content.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup